Physician profile
Brynna Connor
NPI 1295983674
$3,557.90
in general payments reported to CMS, 2019-2025
32 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $116 · 2021: $380 · 2022: $210 · 2023: $892 · 2024: $727 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $676.07 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $628.80 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.71 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $312.49 | 2023-2024 | Qelbree, Qelbree, Xyosted |
| Amgen INC. | $279.88 | 2024-2025 | Otezla, Otezla, Repatha |
| Antares Pharma, INC. | $206.60 | 2024-2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $180.45 | 2023 | Quviviq |
| Therapeuticsmd, INC. | $112.54 | 2019 | |
| Pfizer INC. | $112.05 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $100.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.76 | 2020-2021 | |
| Gilead Sciences, INC. | $57.50 | 2021 | |
| Stryker Corporation | $50.00 | 2022 | |
| Glaxosmithkline, LLC. | $44.20 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Halozyme INC | $41.77 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $41.06 | 2022-2023 | |
| Tms Neurohealth Centers INC. | $27.02 | 2025 | Tms Neurohealth Centers INC. |
| Novo Nordisk INC | $24.15 | 2023 | Wegovy |
| Hologic Sales and Service, LLC | $23.44 | 2025 | Aptima |
| Acella Pharmaceuticals, LLC | $22.43 | 2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.48 | 2025 | Xifaxan |
| Mckesson Medical-Surgical, INC. | $20.00 | 2021 | |
| Astellas Pharma US INC | $18.42 | 2024 | Veozah |
| Tolmar, INC. | $17.12 | 2024 | |
| Amarin Pharma, INC. | $16.76 | 2019 | |
| Irhythm Technologies, INC. | $16.16 | 2024 | Zio Xt Patch, Zio Monitor |
| Mayne Pharma Commercial LLC | $15.91 | 2025 | |
| Genentech USA, INC. | $15.36 | 2020 | |
| Radius Health, INC. | $15.14 | 2023 | Tymlos |
| Arbor Pharmaceuticals, INC. | $14.40 | 2021 | |
| Currax Pharmaceuticals LLC | $14.18 | 2023 | Contrave |
| Alfasigma USA, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brynna Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.